High Velocity Nasal Insufflation Versus Continuous Positive Airway Pressure in COVID 19 Pneumonic Patients

High Velocity Nasal Insufflation Versus Continuous Positive Airway Pressure in COVID 19 Pneumonic Patients With Acute Type 1 Respiratory Failure

Status

Completed

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT07213518

Enrollment

108

Registered

2025-10-09

Start date

2022-01-01

Completion date

2023-01-01

Last updated

2025-10-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

COVID-19 Pneumonia

Keywords

High Velocity Nasal Insufflation, Acute Type 1 Respiratory Failure, COVID 19 Pneumonic Patients, Continuous Positive Airway Pressure

Brief summary

compare the efficacy of High-Velocity Nasal Insufflation (HVNI) versus Continuous Positive Airway Pressure (CPAP) in managing COVID 19 pneumonic patients with acute type 1 respiratory failure

Detailed description

A prospective randomized controlled trial was conducted on 108 patients with COVID 19 pneumonia with acute hypoxemic respiratory failure at Mansoura University Hospitals to compare the efficacy of High-Velocity Nasal Insufflation (HVNI) versus Continuous Positive Airway Pressure (CPAP) in managing COVID 19 pneumonic patients with acute type 1 respiratory failure, focusing on the need for invasive mechanical ventilation (IMV) and 28-day mortality. Patients were randomized into two equal groups: HVNI group and CPAP group. Baseline characteristics, respiratory parameters, and clinical outcomes were recorded.

Interventions

DEVICEHigh Velocity Nasal Insufflation

COVID 19 Pneumonic Patients with Acute Type 1 Respiratory Failure received High Velocity Nasal Insufflation

DEVICEContinuous Positive Airway Pressure

COVID 19 Pneumonic Patients with Acute Type 1 Respiratory Failure received Continuous Positive Airway Pressure

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

SUPPORTIVE_CARE

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Patients aged above 18 years with COVID 19 pneumonia with acute type 1 respiratory failure were included.

Exclusion criteria

* patients with hypercapnic respiratory failure. * patients with a disturbed level of consciousness and/or a high risk of aspiration * individuals with hypotension * patients requiring invasive mechanical ventilation.

Design outcomes

Primary

Measure	Time frame	Description
Correction of hypoxia in COVID 19 Pneumonic Patients with Acute Type 1 Respiratory Failure	6 months	assessment of efficacy of High Velocity Nasal Insufflation versus Continuous Positive Airway Pressure in COVID 19 Pneumonic Patients with Acute Type 1 Respiratory Failure

Countries

Egypt

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026